Marginal zone lymphoma
Conditions
Interventions
experimental group:VR-CAP regimen
Sponsors
He'nan Cancer Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients between 18-70 years old (including 18 and 70 years old); 2. Patients with borderline lymphoma confirmed by histopathology; 3. Patients who have not received anti-tumor chemotherapy before admission; 4. Treatment indications: (1) Tumor related symptoms; (2) There is terminal organ function damage; (3) There is a large mass; (4) Continuous or rapid progress of disease; (5) Patient will; 5. Subjects who must have measurable lesions are defined as: the longest diameter of lymph node lesions in CT cross-sectional images is > 1.5cm; or the longest diameter of extranodal lesions is > 1.0cm; 6. The score of physical state in ECOG must be 0 or 1; 7. Subjects with expected survival time >= 3 months; 8. Subjects whose main organ function met the following criteria 7 days before treatment: (1) Blood routine test: hemoglobin >= 80g / L, neutrophil absolute value >= 1.0 x 10^9 / L, platelet >= 75 x 10^9 / L; (2) Blood biochemistry: total bilirubin = 45ml / min (Cockcroft Gault formula), international standardized ratio (INR) = 50%; 9. Women of childbearing age who can use effective contraceptive measures during the study period and within 6 months after the end of the study; those who are negative in serum or urine pregnancy test within 7 days before the study group; non lactating patients; men who agree to take effective contraceptive measures during the study period and within 6 months after the end of the study period; 10. The subjects who volunteer to join the study and sign the informed consent form, had good compliance and cooperated with the follow-up.
Exclusion criteria
Exclusion criteria: 1. Patients with central nervous system lymphoma are known; 2. ECoG physical strength score > 2; 3. Patients with other active malignant tumors requiring simultaneous treatment; 4. Patients with a history of malignancy. Except for patients with skin basal cell carcinoma, superficial bladder cancer, skin squamous cell carcinoma or cervical carcinoma in situ who have been treated with a possible cure and have not relapsed within 5 years since the start of treatment. 5. Patients who had undergone major surgery or had severe trauma before they were enrolled in the group, whose influence of postoperative trauma was eliminated for less than 14 days; 6. Patients with active tuberculosis. Patients suspected of active TB should be examined for chest X-ray, sputum and excluded by clinical symptoms and signs. 7. Patients with severe acute or chronic infection who need systemic treatment. 8. Patients with heart failure (NYHA class III or IV) and despite appropriate medication, poor control of coronary artery disease or arrhythmia, or a history of myocardial infarction within the first six months of screening; 9. Patients with uncontrolled active hepatitis (HBsAg positive and HBV DNA >= 500iu / ml; HCV RNA positive and abnormal liver function; CO infection with hepatitis B and C); 10. Patients with known positive history of human immunodeficiency virus test or known acquired immunodeficiency syndrome; 11. Patients with decompensated liver disease; 12. Patients who have a history of psychoactive drug abuse and are unable to quit or have mental disorders; 13. According to the judgment of the researcher, there may be other factors that may lead to the forced termination of the study, such as other serious diseases or serious laboratory examination abnormalities or other factors that may affect the safety of the subjects, or related factors such as test data and sample collection family or society. 14. Subjects who are not suitable for the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 2-year PFS; | — |
Secondary
| Measure | Time frame |
|---|---|
| ORR;OS;Adverse events; | — |
Countries
China
Contacts
Public ContactLiu Yanyan
He'nan Cancer Hospital
Outcome results
None listed